Vitamin B ₆ treatment in acute neuroleptic-induced akathisia: A randomized, double-blind, placebo-controlled study

Nursing and Health Professions

• Typical Antipsychotic 100%
• Pyridoxine 100%
• Placebo-Controlled Study 100%
• Akathisia 100%
• Barnes Akathisia Scale 50%
• Placebo 37%
• Symptom 25%
• Clinical Global Impression Scale 25%
• 4 Aminobutyric Acid 25%
• Brief Psychiatric Rating Scale 25%
• Drug Megadose 12%
• DSM-IV 12%
• Serotonin Antagonist 12%
• Motor Dysfunction 12%
• Mental Health Center 12%
• Benzodiazepine Receptor Blocking Agent 12%
• Dopamine Receptor Stimulating Agent 12%
• Cholinergic Receptor Blocking Agent 12%
• Muscarinic Receptor Blocking Agent 12%
• Restlessness 12%
• Neurotransmitter 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo-Controlled Study 100%
• Typical Antipsychotic 100%
• Akathisia 100%
• Pyridoxine 100%
• Placebo 25%
• Symptom 16%
• 4 Aminobutyric Acid 16%
• Motor Dysfunction 8%
• Neurotransmitter 8%
• Serotonin Antagonist 8%
• DSM-IV 8%
• Dopamine Receptor Stimulating Agent 8%
• Restlessness 8%
• Cholinergic Receptor Blocking Agent 8%
• Muscarinic Receptor Blocking Agent 8%
• Benzodiazepine Receptor Blocking Agent 8%

Keyphrases

• Randomized Double-blind Placebo-controlled Study 100%
• Akathisia 100%
• Vitamin B6 100%
• Placebo Groups 16%
• Clinical Global Impression Scale 16%
• Brief Psychiatric Rating Scale 16%
• Placebo 8%
• Schizophrenia 8%
• High Dose 8%
• Psychotic Symptoms 8%
• Schizoaffective 8%
• Beta-blockers 8%
• Double-blind Design 8%
• Mental Hospital 8%
• Aminobutyric Acid 8%
• Dopamine Agonist 8%
• Treatment Strategy 8%
• Serotonin Antagonists 8%
• Twice a Day 8%
• Neurotransmitter Systems 8%
• Scale Assessment 8%
• DSM-IV Diagnoses 8%
• Subjective Awareness 8%
• Subjective Distress 8%
• Antimuscarinics 8%
• Neuroleptic-induced Movement Disorders 8%
• GABAergic Drugs 8%
• Benzodiazepine Antagonist 8%